<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8309206</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1564</journal-id>
<journal-id journal-id-type="nlm-ta">Annu Rev Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Annu. Rev. Immunol.</journal-id>
<journal-title-group>
<journal-title>Annual review of immunology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0732-0582</issn>
<issn pub-type="epub">1545-3278</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26735698</article-id>
<article-id pub-id-type="pmc">5736009</article-id>
<article-id pub-id-type="doi">10.1146/annurev-immunol-041015-055620</article-id>
<article-id pub-id-type="manuscript">NIHMS900194</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genomics of immune diseases and new therapies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lenardo</surname>
<given-names>Michael</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lo</surname>
<given-names>Bernice</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lucas</surname>
<given-names>Carrie L.</given-names>
</name>
</contrib>
<aff id="A1">NIAID Clinical Genomics Program, Molecular Development of the Immune System Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA</aff>
</contrib-group>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<day>20</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>34</volume>
<fpage>121</fpage>
<lpage>149</lpage>
<!--elocation-id from pubmed: 10.1146/annurev-immunol-041015-055620-->
<abstract>
<p id="P1">Genomic DNA sequencing technologies have been one of the great advances of the 21st century â€“ decreasing in cost by 7 orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined XMEN disease caused by the genetic loss of the MAGT1 magnesium transporter. This disease illustrates how genomics yields new fundamental immunoregulatory insights as well as how research genomics is integrated into clinical immunology. At the end, we discuss two other recently described diseases: PASLI (PI3K dysregulation) and CHAI/LATAIE (CTLA-4 deficiency) that show journeys from unknown immunological diseases to new precision medicine treatments using genomics.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>